What Has Been The Evolution of the Dasatinib Drugs Market in Recent Years?
The dasatinib drugs market has seen considerable growth due to a variety of factors.
• In the past few years, the market size for dasatinib drugs has robustly expanded. This market is projected to increase from $1.45 billion in 2024 to $1.55 billion in 2025, growing at a compound annual growth rate (CAGR) of 6.9%.
The marked growth during the historic period could be attributed to factors such as the rising prevalence of chronic myeloid leukemia (CML), advancements in targeted cancer therapies, increased research into tyrosine kinase inhibitors (TKIS), significant investment in oncology research, and a surge in the number of clinical trials.
What Are the Future Growth Projections for the Dasatinib Drugs Market?
The dasatinib drugs market is expected to maintain its strong growth trajectory in upcoming years.
• The market for dasatinib drugs is predicted to undergo a substantial expansion in the upcoming years. It's anticipated to escalate to $2 billion by 2029, with a compound annual growth rate (CAGR) of 6.6%.
The surge during the forecast period is likely due to the escalating investment in cancer drug research, an increasing number of drug-resistant leukemia patients, the rising availability of generic dasatinib drugs, and growing emphasis on reducing the adverse effects of chemotherapy, as well as heightened awareness and early detection of leukemia. The major trends expected during the forecast period include the application of personalized medicine, the incorporation of companion diagnostics, the creation of new formulations, advancements in combined treatments, and the development of biosimilars.
What Are The Core Factors Supporting Growth In The Dasatinib Drugs Market?
The escalating rates of chronic myeloid leukemia (CML), a type of cancer impacting the bone marrow and blood by causing abnormal white blood cell growth, is anticipated to fuel the expansion of the dasatinib drug market. Factors such as lifestyle demographics, unhealthy diets, and mounting environmental hazards are significant contributors to the rise in CML cases. With the ability to restrain the BCR-ABL (gene fusion) activity, a tyrosine kinase protein generated by the Philadelphia chromosome mutation which instigates uncontrolled cancerous white blood cell growth, dasatinib drugs provide effective treatment for CML. Supporting this, the American Cancer Society (ACS), a US-established health entity committed to exterminating cancer, reported an increase in CML cases from 8,860 in 2022 to 8,930 in January 2023 in the United States. Thus, the surging incidences of chronic myeloid leukemia (CML) is fuelling the dasatinib drug market.
What Are The Major Segments Within The Global Dasatinib Drugs Market?
The dasatinib drugsmarket covered in this report is segmented –
1) By Product Type: Tablets, Oral Suspension, Other Products
2) By Indication: Chronic Myeloid Leukemia, Acute Lymphoblastic Leukemia, Other Indications
3) By End User: Hospitals, Specialty Clinics, Home Healthcare
Subsegments:
1) By Tablets: 20 mg Tablets, 50 mg Tablets, 70 mg Tablets, 80 mg Tablets
2) By Oral Suspension: 20 mg Or 5 mL Oral Suspension, 40 mg Or 5 mL Oral Suspension
3) By Other Products: Injectable Formulations, Combination Therapies, Generic Dasatinib Products
Pre-Book The Dasatinib Drugs Global Market Report 2025 Report For Swift Delivery And Comprehensive Insights:
What Emerging Trends Are Influencing The Growth Of The Dasatinib Drugs Market?
Principal enterprises performing in the dasatinib drugs sector are concentrating on creating generic drugs to augment their market influence, provide reasonably-priced treatment alternatives and amplify their reach to patients. In the dasatinib market, generic drugs offer treatments that are more budget-friendly which enhances patient accessibility and encourages competition while diminishing healthcare expenses for patients. For instance, Apotex Corp., a pharmaceutical venture based in Canada, inaugurated the first generic variant of Sprycel dasatinib in the United States in September 2024 to combat certain types of leukemia in adults and children. This economically efficient replacement boosts access to top-grade treatment alternatives. Its launch constitutes a noteworthy stride in fostering competition and cutting charges in the dasatinib market.
Who Are the Key Players In The Dasatinib Drugs Market?
Major companies operating in the dasatinib drugs market are:
• Bristol-Myers Squibb Company
• AstraZeneca plc
• Novartis AG
• Gilead Sciences Inc.
• Amgen Inc.
• Teva Pharmaceutical Industries Ltd.
• Otsuka Pharmaceutical Co. Ltd.
• Sandoz Group AG
• Hetero Drugs Limited
• Sun Pharmaceutical Industries Limited
• MSN Laboratories Pvt. Ltd.
• Aurobindo Pharma Limited
• Dr. Reddy's Laboratories Limited
• Intas Pharmaceuticals Ltd.
• Cipla Limited
• Hikma Pharmaceuticals plc
• Lupin Limited
• Zhejiang Hisun Pharmaceutical Co. Ltd.
• Biocon Limited
• Alkem Laboratories Limited
• Glenmark Pharmaceuticals Limited
• Torrent Pharmaceuticals Limited
• Alembic Pharmaceuticals Limited
• Mylan N.V.
• Manus Aktteva Biopharma LLP
What Is The Most Dominant Region In The Dasatinib Drugs Market?
North America was the largest region in the dasatinib drugs market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the dasatinib drugs market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
